• Clinical and Experimental Pediatrics
• /
• 제50권10호
• /
• pp.965-969
• /
• 2007

목 적 : Antistreptolysin O(ASO)는 인종, 지역, 역학적 요소에 따라 정상치가 다르므로 시기별, 지역마다 각 연령별 정상치가 필요하다. 경인지역에서 신생아부터 29세까지를 대상으로 연령별 ASO치의 분포를 분석하여 이 지역에서 사용할 수 있는 ASO의 소아 정상치를 확립하고자 하였다. 방 법 : 경인지역에서 2002년 1월에서 2003년 2월 사이의 신생아부터 29세까지 753명(남자 381명, 여자 372명)의 혈청을 이용하여 혈청 내 ASO치를 측정하였다. 전체를 각각 연령별로 분석하고 다시 신생아 군, 0-3세 군, 4-6세 군, 7-9세 군, 10-19세 군과 20-29세 군으로 나누어 ULN를 구하였다. 결 과 : 전체 대상의 ASO치는 $149.9{\pm}197.0IU/mL$였으며, 신생아 군에서 $83.4{\pm}78.7IU/mL$이었고, 이후 점차 떨어져 1세 군에서는 $26.7{\pm}43.0IU/mL$로 가장 낮았다. 이후 점차 증가하여 9세 군에서 $318.0{\pm}250.8IU/mL$로 최고값에 도달한 후 다시 감소하였다. ASO 상한값(upper Limit of Normal: ULN)은 0-3세 군에서 40 IU/mL, 신생아 군에서 122 IU/mL, 4-6세 군에서 113 IU/mL, 7-9세 군에서 489 IU/mL, 10-19 세 군에서 433 IU/mL, 20-29 세 군에서 122 IU/mL 였다. 결 론 : 이상으로 경인지역에서 2002년 1월에서 2003년 2월 사이의 신생아부터 29세까지의 연령별 ASO치의ULN을 설정하였으며, ASO 값의 판정은 소아와 성인간에 다른 ULN을 적용하여야 함은 물론 소아에서도 여러 연령별로 나누어서 ASO ULN치를 적용하여야 함을 알 수 있었다. 이 결과는 향후 환자들의 ASO 결과를 임상적으로 해석하는데 도움이 될 것으로 사료된다.

• 한국임상약학회지
• /
• 제19권2호
• /
• pp.146-152
• /
• 2009

Purpose : 본 연구의 목적은 항암치료로 인한 빈혈환자의 치료에서 epoetin alpha (rHuEPO) 피하주사 시, 주일회 요법과 주삼회요법의 헤모글로빈(hemoglobin, Hb) 상승 효과를 비교하는 것이다. Methods : 본 연구는 1999년 3월부터 2005년 3월까지 국립암센터에서 항암치료로 인한 빈혈로 epoetin alpha를 투여 받은 환자를 대상으로 의무기록의 자료를 후향적으로 수집하여 분석하였다. 연구에 포함된 환자는 rHuEPO 10,000 IU 주삼회투여군(n = 127)과 20,000 IU 주일회투여군(n = 81)으로 구분되었으며, 이들은 필요에 따라 경구용 철분보조제를 섭취하였다. Epoetin alpha 치료 시작 후 최대 8주까지 2주 간격으로 Hb 수치변화를 분석하였다. Results : 치료 시작 시점의 rHuEPO 10,000 IU 주삼회투여군과 20,000 IU 주일회투여군의 평균 Hb수치는 유사하였 다 (9.4 g/dL vs. 9.7 g/dL). Epoetin alpha 치료 후 8주까지 두 그룹간의 헤모글로빈 수치의 상승 정도에는 유의한 차이가 없었다 ($1.57{\pm}1.39$ g/dL vs. $1.68{\pm}1.35$ g/dL, p=0.59). 또한 경구용 철분보조제 투여여부, cisplatin 포함 항암제 투여여부 및 성별에 따른 군의 분류에 있어서도 rHuEPO 10,000 IU 주삼회투여군과 20,000 IU 주일회투여군의 평균 Hb 상승수치는 유의한 차이를 보이지 않았다. Conclusion : 한국인에서 항암치료로 인한 빈혈의 치료 시에 rHuEPO 20,000 IU 주일회투여 용법은 10,000 IU 주 삼회투여 용법과 유사한 Hb 상승효과를 가진다.

• 대한불안의학회지
• /
• 제9권1호
• /
• pp.3-9
• /
• 2013

Intolerance of uncertainty (IU) is defined as the tendency to react negatively on an emotional, cognitive, and behavioral level to uncertain situations and events. However, this definition is somewhat categorical and does not explain the phenomenology of IU. Intolerance of uncertainty scale (IUS), the standard measure of IU, was considered to have two factors : 'unacceptability and avoidance of uncertainty' and 'uncertainty leading to the inability to act'. IU may be a cognitive vulnerability factor for clinical worry and generalized anxiety disorder (GAD). A number of moderators and mediators including cognitive avoidance, experiential avoidance and rumination influence the relationship between IU, worry, obsessive-compulsive symptoms, anxious and depressive symptoms. IU may be more strongly related to the symptoms of GAD than to symptoms of other anxiety disorders including obsessive-compulsive disorder (OCD), and major depressive disorder. IU may serve as an important transdiagnostic feature across anxiety and depressive disorders. Incorporating IU-specific treatment components into therapeutic protocols may result in pervasive benefits, and not only for those with GAD or OCD, but for people with any anxiety disorder or with depression.

• 한국임상수의학회지
• /
• 제15권1호
• /
• pp.162-170
• /
• 1998

Present experiments were undertaken in order to determine the normal hematological and blood chemical values of elks raised in Korea. Blood samples were collected from 22 healthy adult (5~10 years old) male elks raised in Kyung-pook prefecture and examined for 9 hematological and 15 blood chemical parameters using automatic blood cell counter and automatic blood chemical analyzer. The mean hematological values were determined as PCV : 34.23%, RBC count : $6.70{\times}10^{6}/{\mu}l, Hb : 12.15g/61, WBC count : 3.17{\times}10^{3}/{\mu}l$, neutrophil : 54.09%, eosinophil : 12.27%, Iymphocyte : 28.86%, monocyte : 5.23%, and platelet : $39.94$\times$10^{5}/{\mu}l$

• KSBB Journal
• /
• 제9권1호
• /
• pp.48-54
• /
• 1994

HEK 세포 배양액 중에 존재하는 scu-PA와 tc-PA의 보다 정확한 측정을 위해 fibrin plate법과 기존의 amidolytic 방법을 변형시킨 측정법을 이용했다. 1%의 저혈청 배지를 이용한 T-flask 배양에서 $1.65{\times}10^6$(viable cells/ml)의 최대 세포수에 도달하여 1670(IU/ml)의 scu-PA 생산량을 보였으며 평균 10% 미만이 변환율을 보였다. 또한 Spinner vessel에서의 회분배양시 최대 세포수가 $4.43{\times}10^6(total cells/ml)$ 와 1560(IU/ml)의 scu-PA 생산량을 나타냈으며 평균 11.4%의 변환율을 보였다. 연속배양에서는 0.449(1/day)의 비생육속도와 $3.13{\times}10^{-4}(IU/cell)$의 비생산속도를 보였으며 평균 10.18% 정도의 전환율을 보였다. 이는 회분식 및 유가식 배양 결과와 큰 차이가 없으며 배양공정에 관계없이 약 90% 이상의 회수율이 가능하다는 것을 의미한다.

• Toxicological Research
• /
• 제33권4호
• /
• pp.343-350
• /
• 2017

Lamivudine belongs to the set of antiviral agents effective against hepatitis B virus infection. Given case reports on liver injuries after certain antiviral agent treatments, this study examined the effects of lamivudine on alanine aminotransferase (ALT) and total bilirubin (TB) using a medical system database. A total of 1,321 patients taking lamivudine alone or with others were evaluated using laboratory hits in an electronic medical system at Seoul National University Hospital from 2005 through 2011. The patients were grouped according to prior ALT results: G#1, ALT < 40 IU/L; G#2, 40 IU/L ${\leq}$ ALT < 120 IU/L; G#3, 120 IU/L ${\leq}$ ALT < 240 IU/L; and G#4, ALT ${\geq}$ 240 IU/L. In G#1 and G#2 patients, lamivudine or adefovir treatment decreased ALT and TB compared to prior values. In G#3 and G#4 patients with three times the upper limit of normal (ULN) ${\leq}$ ALT < 15 times the ULN, both ALT and TB were decreased after treatment with lamivudine alone, or adefovir following lamivudine therapy, indicating that lamivudine therapy ameliorated liver functions. However, in G#4 patients who experienced severely advanced hepatitis (ALT ${\geq}$ 15 times the ULN, or ${\geq}$ 600 IU/L), lamivudine augmented TBmax ($6.3{\rightarrow}13.3mg/dL$) despite a slight improvement in ALT ($839{\rightarrow}783IU/L$), indicative of exacerbation of bilirubinemia. Patients who used adefovir after lamivudine also showed a high incidence of hyperbilirubinemia when they experienced severely advanced hepatitis. Treatment with adefovir alone did not show the effect. In conclusion, lamivudine may increase the risk of hyperbilirubinemia in patients with severely advanced hepatitis, implying that caution should be exercised when using lamivudine therapy in certain patient populations.

• KSBB Journal
• /
• 제32권2호
• /
• pp.96-102
• /
• 2017

The lignocellulose that is a major component of spent coffee ground was degraded and saccharified. To implement the spent coffee, after several pre-treatments, inoculation of Phanerochaete chrysosporium and solid-state fermentation were conducted. The optimal temperature of the enzymes (lignin peroxidase, manganese peroxidase, xylanase, laccase, and cellulase) for degradation of lignocellulose by P. chrysosporium was found. We also measured the maximum activity of enzymes (lignin peroxidase 0.15 IU/mL, manganese peroxidase 0.90 IU/mL, laccase 0.11 IU/mL, cellulase 5.87 IU/mL, carboxymethyl cellulase 9.52 IU/mL, xylanase 1.16 IU/mL) used for the process. As a result, 4.73 mg/mL of reduced sugar was obtained and 61.02% of lignin was degraded by solid state fermentation of P. chrysosporium on spent coffee ground.

• 한국임상수의학회지
• /
• 제13권2호
• /
• pp.127-129
• /
• 1996

The study was conducted to determine normal blood and serum chemical values on deer. Normal blood and serum chemical values were studied in 8 healthy deers bred at Dalseung Park in Taegu. The values were analyzed with a blood chemical analyzer and calculated by Chawen's statistical analysis. The blood values of RBC, WBC and PCV were $9.73{\pm}1.19{\times} 10^{6}/{\mu}l, 3.37{\pm}0.88{\times}10^{3}/{\mu}l, 47.25{\pm}4.65 % respectively. The serum chemical value were: GOT; 83.0{\pm}39.4 IU/L, GPT; 50.12{\pm}25.83 IU/L, BUN; 36.63{\pm}8.70 mg/dl. CPK ; 1,296{\pm}495 IU/L, ALP; 238{\pm}54 IU/L, glucose; 143{\pm}52 mg/dl, total protein; 6.95{\pm}0.61 g/dl, amylase ; 116.0{\pm}34.5 IU/L,$ respectively. These values will be clinically helpful to diagnose the disease of deer.

• 한국임상수의학회지
• /
• 제15권1호
• /
• pp.79-82
• /
• 1998

This study was performed to determine the changes of serum enzyme activities in rats with hepatic injury induced by the administration of AAPH. Minor behavioral change, brittleness of skin hair and decreased water and fled intake were observed in rats administered intraperitoneally with AAPH. Serum AST and ALT activities pre-treatment were $65{\pm} 13.8 and 32{\pm}$ 12.6 IU/L, respectively and increased sharply from 2 hours of administration and reached $1248{\pm} 77.6 and 946{\pm}$ 45.6 IU/L, respectively at 48 hours of administration. Serum ALP and $\gamma -GTP activities pretreatment were 221 {\pm} 75.6 and 2.2{\pm}$ 0.35 IU/L respectively and increased sharply from 8 hours of administration and reached $767{\pm} 44.9 IU/L and 8.0{\pm} 1.23 IU/L,$ respectively at 48 hours of administration.

• Journal of Preventive Medicine and Public Health
• /
• 제50권4호
• /
• pp.278-281
• /
• 2017

Since 2006, type 1 diabetes in Finland has plateaued and then decreased after the authorities' decision to fortify dietary milk products with cholecalciferol. The role of vitamin D in innate and adaptive immunity is critical. A statistical error in the estimation of the recommended dietary allowance (RDA) for vitamin D was recently discovered; in a correct analysis of the data used by the Institute of Medicine, it was found that 8895 IU/d was needed for 97.5% of individuals to achieve values ${\geq}50nmol/L$. Another study confirmed that 6201 IU/d was needed to achieve 75 nmol/L and 9122 IU/d was needed to reach 100 nmol/L. The largest meta-analysis ever conducted of studies published between 1966 and 2013 showed that 25-hydroxyvitamin D levels <75 nmol/L may be too low for safety and associated with higher all-cause mortality, demolishing the previously presumed U-shape curve of mortality associated with vitamin D levels. Since all-disease mortality is reduced to 1.0 with serum vitamin D levels ${\geq}100nmol/L$, we call public health authorities to consider designating as the RDA at least three-fourths of the levels proposed by the Endocrine Society Expert Committee as safe upper tolerable daily intake doses. This could lead to a recommendation of 1000 IU for children <1 year on enriched formula and 1500 IU for breastfed children older than 6 months, 3000 IU for children >1 year of age, and around 8000 IU for young adults and thereafter. Actions are urgently needed to protect the global population from vitamin D deficiency.